Lincoln Pharmaceuticals Ltd.

₹603.25

-14.4 (-2.3%)

LINCOLN Share Price

Pharmaceuticals & Biotechnology

As on March 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,209 Cr

P/E Ratio14.67

Dividend Yield0.03 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	617.79	Bearish
10-DMA	619.72	Bearish
20-DMA	622.27	Bearish
50-DMA	536.6	Bullish
100-DMA	522.21	Bullish
200-DMA	536.95	Bullish

Historical Performance

1 Year

14.5%

3 Years

82.9%

5 Years

141.1%

10 Years

281.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	6,232	5,805	5,103	4,721	4,242
Total Expenditure	5,217	4,806	4,211	3,766	3,370
Other Income	225	344	225	100	57
Operating Profit	1,240	1,343	1,117	1,055	928
Interest	19	15	20	15	16
Depreciation	129	106	92	81	76
Profit Before Tax	1,092	1,222	1,005	959	837
Consolidated Net Profit	823	933	729	694	623
Adjusted EPS	41	47	36	35	31

Compounded Sales Growth

10 Years:9.3

5 Years:10

3 Years:5.7

TTM:1.4

Compounded Profit Growth

10 Years:28.3

5 Years:9.9

3 Years:3.5

TTM:-2.5

Stock Price CAGR

10 Years:15.2

5 Years:20.4

3 Years:22.6

TTM:14.5

Return on Equity

10 Years:14.5

5 Years:31.1

3 Years:36.4

last year:41.1

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	200	200	200	200	200
Total Reserves	6,516	5,728	4,824	4,128	3,464
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	191	152	380	110	261
Other Current Liabilities	148	152	145	98	134
Short Term Borrowings	---	11	20	20	---
Total Liabilities	8,219	7,254	6,365	5,546	4,873
Capital Work in Progress	45	35	67	161	17
Long Term Loans & Advances	1,106	797	882	318	468
Currents Investments	1,737	1,389	913	968	807
Short Term Loans and Advances	809	695	570	676	718
Total Current Assets	5,248	4,629	3,911	3,731	3,277
Total Assets	8,219	7,254	6,365	5,546	4,873
Adjusted Book Value	335	296	251	216	183

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 14.67, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 22.6%, indicating sustained price appreciation.
The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹1240 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹6232 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1159427.3

No. of Shares: 1922 (Approx)

Performance:15.9%

P/L: ₹159427.3

NIFTY Performance: 3.4%

1 day Top Gainers